Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

NCT05161936 ·Status: TERMINATED ·Phase: PHASE2

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

NCT02547805 ·Status: COMPLETED ·Phase: PHASE2

Long Term Extension Study in Patients With Primary Hyperoxaluria

NCT04042402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393 ·Status: ACTIVE_NOT_RECRUITING

Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood

NCT00150566 ·Status: COMPLETED ·Phase: PHASE3

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

NCT06225882 ·Status: RECRUITING

Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease

NCT00151918 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

NCT05993416 ·Status: NO_LONGER_AVAILABLE

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT05650112 ·Status: UNKNOWN ·Phase: PHASE1

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486 ·Status: COMPLETED ·Phase: PHASE1

A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

NCT00416520 ·Status: COMPLETED ·Phase: PHASE3

A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00542815 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

NCT05412472 ·Status: COMPLETED ·Phase: PHASE1

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

NCT00506441 ·Status: COMPLETED ·Phase: PHASE3

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00772382 ·Status: COMPLETED ·Phase: PHASE3

Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

NCT03346369 ·Status: UNKNOWN ·Phase: PHASE3

Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults

NCT00880750 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease

NCT00234702 ·Status: COMPLETED ·Phase: PHASE2

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

NCT01022424 ·Status: COMPLETED ·Phase: PHASE3

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

NCT04580420 ·Status: RECRUITING ·Phase: PHASE2

Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis

NCT02000219 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

NCT03847909 ·Status: COMPLETED ·Phase: PHASE2

A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.

NCT00150540 ·Status: COMPLETED ·Phase: PHASE3

Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

NCT05031546 ·Status: APPROVED_FOR_MARKETING

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

NCT00844545 ·Status: COMPLETED ·Phase: PHASE2